Skip to main content

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Modelo predictivo del riesgo de infección y rechazo después del trasplante renal basado en la combinadición de parámetros clínicos y biomarcadores.

IP: Francesc Moreso Mateos
Collaborators: Joana Sellarés Roig, Concepció Jacobs Cachá, Maria de Oreto Prat Canet, Manel Perelló Carrascosa, Romina Dieli Crimi, Nestor Gabriel Toapanta Gaibor, Romina Dieli Crimi
Funding agency: Instituto de Salud Carlos III
Funding: 87120
Reference: PI18/01832
Duration: 01/01/2019 - 31/12/2022

Relación entre los niveles de tacrolimus y/o dosis de micofenolato y la modulación de los genes de rechazo en biopsias de seguimiento del aloinjerto renal

IP: Daniel Serón Micas
Collaborators: Joana Sellarés Roig, Concepció Jacobs Cachá, Manel Perelló Carrascosa
Funding agency: Instituto de Salud Carlos III
Funding: 81070
Reference: PI18/01704
Duration: 01/01/2019 - 31/12/2021

Apolipoproteína AIb como biomarcador y diana terapéutica de la glomeruloesclerosis segmentaria y focal idiopática (GESF)

IP: Joan López Hellin
Collaborators: José Antonio Arranz Amo, Joana Sellarés Roig, Maria Teresa Salcedo Allende, Concepció Jacobs Cachá
Funding agency: Instituto de Salud Carlos III
Funding: 88935
Reference: PI14/00275
Duration: 01/01/2015 - 30/06/2018

Promoting regeneration versus tubulointerstitial fibrosis in progressive renal disease: Novel molecular pathways

IP: Anna Meseguer Navarro
Collaborators: Joan López Hellin, Maria Teresa Salcedo Allende, Concepció Jacobs Cachá
Funding agency: Sociedad Española de Nefrología (S.E.N.)
Funding: 18000
Reference: SENEFRO-2012-01
Duration: 06/10/2012 - 05/10/2014

Related news

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

During the last year, the collaboration between Vall d’Hebron and ZeClinics has found three nanobody candidates with potent anticancer properties in zebrafish model.

Related professionals

Hug Cuellar Calabria

Hug Cuellar Calabria

Senior researcher
Molecular Medical Imaging
Read more
Olalla Pancorbo Rosal

Olalla Pancorbo Rosal

Research technician
Stroke research
Read more
Javier Limeres Freire

Javier Limeres Freire

Predoctoral researcher
Cardiovascular Diseases
Read more
Ferran Casals Riera

Ferran Casals Riera

Research technician
Ophtalmology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.